GT Biopharma Inc. (GTBP)

Acerca

GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates, bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic agents. Its drug candidates include OXS-1550, OXS-2175 and OXS-4235. OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-2175 is a small molecule therapeutic candidate for the treatment of triple-negative breast cancer. OXS-4235 is also a small molecule therapeutic candidate. It is engaged in developing central nervous system (CNS) drugs.